Data from BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in <i>BRAF</i>-Mutated Colorectal Cancers

Zhiyu Tang,Xi Yuan,Rong Du,Shing-Hu Cheung,Guoliang Zhang,Jing Wei,Yuan Zhao,Yingcai Feng,Hao Peng,Yi Zhang,Yunguang Du,Xiaoxia Hu,Wenfeng Gong,Yong Liu,Yajuan Gao,Ye Liu,Rui Hao,Shengjian Li,Shaohui Wang,Jiafu Ji,Lianhai Zhang,Shuangxi Li,David Sutton,Min Wei,Changyou Zhou,Lai Wang,Lusong Luo

DOI: https://doi.org/10.1158/1535-7163.c.6538260.v1

2023-01-01

Abstract:AbstractOncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAFV600E metastatic melanoma, their clinical efficacy in BRAFV600E colorectal cancer is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors. Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigation. In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAFV600E and EGFR mutation/amplification. In BRAFV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAFV600E mutation. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAFV600E mutation. Mol Cancer Ther; 14(10); 2187–97. ©2015 AACR.